Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments. NICE technology appraisal guidance 862
National Institute for Health and Care Excellence (NICE)
Record ID 32018011903
English
Details
Project Status:
Completed
URL for project:
https://www.nice.org.uk/guidance/ta862
Year Published:
2023
URL for published report:
https://www.nice.org.uk/guidance/ta862
English language abstract:
An English language summary is available
Publication Type:
Full HTA
Country:
England
MeSH Terms
- Breast Neoplasms
- Trastuzumab
- Antineoplastic Combined Chemotherapy Protocols
- Immunoconjugates
- Antineoplastic Agents, Immunological
Contact
Organisation Name:
National Institute for Health and Care Excellence
Contact Address:
Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT
Contact Name:
nice@nice.nhs.uk
Contact Email:
nice@nice.nhs.uk
Copyright:
National Institute for Health and Care Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.